Abstract
Overview
Introduction
Sales of the Top 20 cancer therapy brands in each of the seven major markets
totaled $24.5 billion in 2006 and are forecast to grow at a CAGR of 6.6% to
$45.9 billion by 2016. Four newly marketed drugs are expected to become part
of the Top 20 cancer therapy brands during the forecast period and are set to
increase the 2016 sales of the existing Top 20 cancer therapy brands to $52.7
billion.
Scope
- Overview of the current Top 20 cancer therapy brands market
- Individual country, 5EU and seven-market sales forecasts from 2006 to 2016
for the leading cancer therapy brands
- Segmentation and analysis of market dynamics by country sales, drug class,
indication, company and impacted events
- Detailed product profiles and discussion of assumptions and events used in
forecast analysis
Highlights
Four newly marketed drugs are expected to become part of the Top 20 cancer
therapies during the forecast period: Sutent (sunitinib; Pfizer), Nexavar
(sorafenib; Onyx/Bayer), Vectibix (panitumumab; Amgen) and Tykerb (lapatinib;
GSK). These products combined with the existing Top 20 cancer therapies are
set to reach $52.7 billion in sales by 2016.
The Top 20 cancer therapy brands are forecast to experience 144 different
events between 2007 and 2016. Considering the fact that many of these events
will take place in each of the seven major markets, Datamonitor expects the
Top 20 cancer therapy brands to experience 792 events across the 7MM.
The 35 drugs that make up the Top 20 cancer therapy brands have gained
approval in 18 different tumor types. Three of the ' big four' tumor types
boast the highest number of leading cancer therapy brands namely: breast
cancer with 18 of the 35 forecasted drugs, non-small cell lung cancer with
eight, and colorectal cancer with seven.
Reasons to Purchase
- Understand market specific drivers and predict the future potential of key
cancer therapy brands
- Quantify the impact of key patent expiries and product launches and gain a
valuable insight into the market dynamics
- Consider, assess and react to opportunities and risks influencing the
leading cancer therapy brands
| 
View Cart
